Should I get a comprehensive genomic panel for Mantle Cell Lymphoma

Genomic Testing for Mantle Cell Lymphoma: What You Should Know

This is an excellent question, and the answer depends on several factors specific to your situation. Let me explain what the evidence shows and what questions to discuss with your team.

What the Guidelines Recommend

According to the NCCN Guidelines for Mantle Cell Lymphoma, genomic testing is considered essential at diagnosis, but the specific tests recommended include:

Essential Testing:

• TP53 sequencing - This is particularly important because TP53 mutations are associated with poor prognosis in mantle cell lymphoma patients treated with conventional therapy, including transplant
• Immunophenotyping with specific markers (CD20, CD5, cyclin D1, CD10, CD23, BCL2, BCL6, SOX11, Ki-67)
• Flow cytometry to confirm diagnosis

Useful Under Certain Circumstances:

• SOX11 or IGHV sequencing - These may help determine if you have clinically indolent (slower-growing) mantle cell lymphoma
• Karyotype or FISH testing - To look for t(11;14) and other chromosomal changes

Why This Matters for Your Care

The NCCN Guidelines emphasize that TP53 mutation status is critical because:

• It helps predict how your cancer will respond to treatment
• It influences which therapies your doctor will recommend
• Patients with TP53 mutations are strongly recommended to consider clinical trials

The Difference: Targeted vs. Comprehensive Panels

A "comprehensive genomic panel" tests many genes at once, while the NCCN-recommended approach focuses on specific, clinically actionable tests for mantle cell lymphoma. The key question is whether a broader panel would change your treatment decisions — this is something your oncologist is best positioned to answer based on:

• Whether you've already had TP53 sequencing
• Your specific disease stage and characteristics
• Whether you're considering clinical trials
• Your treatment plan (standard therapy vs. clinical trial eligibility)

Questions to Ask Your Oncology Team

1. Have I already had TP53 sequencing performed? If yes, what were the results?
2. Do you recommend additional genomic testing beyond what's already been done? If so, why?
3. Would a comprehensive panel change my treatment recommendations?
4. Am I a candidate for clinical trials, and would additional genomic data help identify trials for me?
5. If I have a TP53 mutation, what does that mean for my treatment options?
6. Are there any out-of-pocket costs for additional testing I should know about?

Important Context

The NCCN Guidelines note that clinical trials are strongly recommended for patients with TP53 mutations, as these patients may not respond as well to conventional therapy. If you're considering a clinical trial, your oncologist may recommend additional genomic testing to match you with appropriate studies.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.